163.26  4.88 (3.08%)		07-24 16:00
Open: 159.21 High: 164.33 Volume: 1,138,681		Pre. Close: 158.38 Low: 158.31 Market Cap: 11,308(M)

Short term
Mid term
Targets	6-month :	198.38	1-year :	231.71
Resists	First :	169.85	Second :	198.38
Pivot price	161.26
Supports	First :	150.65	Second :	138.78
MAs	MA(5) :	162.33	MA(20) :	160.57
	MA(100) :	178.62	MA(250) :	252.85
MACD	MACD :	2	Signal :	1.9
%K %D	K(14,3) :	43.4	D(3) :	50.1
RSI	RSI(14): 54.9
52-week	High :	354.88	Low :	138.78

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ PODD ] has closed below upper band by 31.9%. Bollinger Bands are 60.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	164.41 - 165.4	165.4 - 166.35
Low:	156 - 157.15	157.15 - 158.25
Close:	161.46 - 163.19	163.19 - 164.84

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Fri, 24 Jul 2026
Insulet Corp (PODD) Shares Surge 3.1% -- What GF Score of 81 Tel - GuruFocus

Fri, 24 Jul 2026
Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

Fri, 24 Jul 2026
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire

Thu, 23 Jul 2026
Deadline Alert: Insulet Corporation (PODD) Shareholders Who - GlobeNewswire

Thu, 23 Jul 2026
SueWallSt Reminds Insulet Corporation Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 31, 2026 - PODD - PR Newswire

Wed, 22 Jul 2026
PODD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Insulet Corporation Securities Lawsuit - Contact Levi & Korsinsky - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	69 (M)
Shares Float	69 (M)
Held by Insiders	0.3 (%)
Held by Institutions	105 (%)
Shares Short	4,850 (K)
Shares Short P.Month	4,230 (K)

EPS	4.26
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	18.8
Profit Margin	10.4 %
Operating Margin	16 %
Return on Assets (ttm)	9.7 %
Return on Equity (ttm)	23 %
Qtrly Rev. Growth	33.9 %
Gross Profit (p.s.)	29.74
Sales Per Share	41.87
EBITDA (p.s.)	8.69
Qtrly Earnings Growth	159 %
Operating Cash Flow	619 (M)
Levered Free Cash Flow	253 (M)

PE Ratio	38.23
PEG Ratio	1.3
Price to Book value	8.67
Price to Sales	3.89
Price to Cash Flow	18.25

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.